Purcell et al. explored the impact of neuroendocrine differentiation (NED), responsible for increased tumor aggressiveness, resistance to treatments, and poor prognosis, on the sensitivity of prostate cancer cells to ClpP-activating imipridones. Here, CLPP is linked to prostate carcinoma.